The metastasis suppressor, NDRG1, attenuates oncogenic TGF-β and NF-κB signaling to enhance membrane E-cadherin expression in pancreatic cancer cells
- 18 December 2018
- journal article
- research article
- Published by Oxford University Press (OUP) in Carcinogenesis
- Vol. 40 (6) , 805-818
Abstract
The metastasis suppressor, N-myc downstream-regulated gene-1 (NDRG1), plays multifaceted roles in inhibiting oncogenic signaling and can suppress the epithelial mesenchymal transition (EMT), a key step in metastasis. In this investigation, NDRG1 inhibited the oncogenic effects of transforming growth factor-β (TGF-β) in PANC-1 pancreatic cancer cells, promoting expression and co-localization of E-cadherin and β-catenin at the cell membrane. A similar effect of NDRG1 at supporting E-cadherin and β-catenin co-localization at the cell membrane was also demonstrated for HT-29 colon and CFPAC-1 pancreatic cancer cells. The increase in E-cadherin in PANC-1 cells in response to NDRG1 was mediated by the reduction of three transcriptional repressors of E-cadherin, namely SNAIL, SLUG and ZEB1. To dissect the mechanisms how NDRG1 inhibits nuclear SNAIL, SLUG and ZEB1, we assessed involvement of the nuclear factor-κB (NF-κB) pathway, as its aberrant activation contributes to the EMT. Interestingly, NDRG1 comprehensively inhibited oncogenic NF-κB signaling at multiple sites in this pathway, suppressing NEMO, Iĸĸα and IĸBα expression, as well as reducing the activating phosphorylation of Iĸĸα/β and IĸBα. NDRG1 also reduced the levels, nuclear co-localization and DNA-binding activity of NF-κB p65. Further, Iĸĸα, which integrates NF-κB and TGF-β signaling to upregulate ZEB1, SNAIL and SLUG, was identified as an NDRG1 target. Considering this, therapies targeting NDRG1 could be a new strategy to inhibit metastasis, and as such, we examined novel anticancer agents, namely di-2-pyridylketone thiosemicarbazones, which upregulate NDRG1. These agents downregulated SNAIL, SLUG and ZEB1 in vitro and in vivo using a PANC-1 tumor xenograft model, demonstrating their marked potential.Keywords
Funding Information
- National Health and Medical Research Council of Australia (1060482)
- Priority-driven Collaborative Cancer Research Scheme (1086449)
- University of Sydney
- NHMRC Senior Principal Research (1062607)
- NHMRC Peter Doherty Early Career Fellowship (1037323)
- Cancer Institute New South Wales Early Career Fellowship (12-ECF2-17)
- NHMRC RD Wright Fellowship (APP1140447)
This publication has 46 references indexed in Scilit:
- Proteolytic cleavage and truncation of NDRG1 in human prostate cancer cells, but not normal prostate epithelial cellsBioscience Reports, 2013
- The Iron Chelators Dp44mT and DFO Inhibit TGF-β-induced Epithelial-Mesenchymal Transition via Up-Regulation of N-Myc Downstream-regulated Gene 1 (NDRG1)Journal of Biological Chemistry, 2012
- N‐myc downstream regulated gene 1 modulates Wnt‐β‐catenin signalling and pleiotropically suppresses metastasisEMBO Molecular Medicine, 2012
- Claudin-1 Up-regulates the Repressor ZEB-1 to Inhibit E-Cadherin Expression in Colon Cancer CellsGastroenterology, 2011
- Novel Thiosemicarbazone Iron Chelators Induce Up-Regulation and Phosphorylation of the Metastasis Suppressor N-myc Down-Stream Regulated Gene 1: A New Strategy for the Treatment of Pancreatic CancerMolecular Pharmacology, 2011
- Nuclear Factor-κB–Dependent Epithelial to Mesenchymal Transition Induced by HIF-1α Activation in Pancreatic Cancer Cells under Hypoxic ConditionsPLOS ONE, 2011
- Phenotype and Genotype of Pancreatic Cancer Cell LinesPancreas, 2010
- Shared Principles in NF-κB SignalingCell, 2008
- A class of iron chelators with a wide spectrum of potent antitumor activity that overcomes resistance to chemotherapeuticsProceedings of the National Academy of Sciences, 2006
- The Evolution of Iron Chelators for the Treatment of Iron Overload Disease and CancerPharmacological Reviews, 2005